Pieris Pharmaceuticals' Collaborator Presents Promising

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Pieris Pharmaceuticals' Collaborator Presents Promising Preclinical Data on Tetraspecific Infectious Disease Anticalin Program at ASM Conference

BOSTON, MA --(Marketwired - September 15, 2015) - Pieris Pharmaceuticals, Inc . ( NASDAQ : PIRS ), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform, announced today that one of its partners, Sanofi, presented preclinical data on the companies' multispecifics program at an infectious disease conference. The tetraspecific Anticalin-based protein comprises four distinct Anticalin proteins, each specific for one of four different families of siderophores from Pseudomonas aeruginosa , collectively engaging twenty targets with high affinity and specificity.

The data presented September 10, 2015 at the American Society for Microbiology (ASM) Conference on Pseudomonas in Washington, DC, by Dr. Carsten Corvey, Global Sanofi Project leader, provided an overview of the drug-like properties of this complex protein, as well as promising in vivo activity in a chronic Pseudomonas aeruginosa infection animal model. The data demonstrate that the individual Anticalin polypeptides of the tetraspecific construct specifically bind to their respective targets in the low to sub nM range, achieving the desired efficacy in vitro and in a chronic infection rat model, in addition to exhibiting desired manufacturability and stability criteria.

Dr. Laurent Fraisse, Vice President Infectious Diseases, Sanofi R&D, commented, "Anticalins are optimally suited for addressing several targets with a multispecific protein and have shown great promise to address infectious diseases, in particular. We look forward to further advancing this program into IND-enabling studies."

Pieris President and CEO, Stephen Yoder, commented, "Our tetraspecific Anticalin program with Sanofi is one of the best examples of how our proprietary protein drug class is highly differentiated over antibody approaches. The benefits of engaging multiple targets with a single protein under one IND could be numerous and, in this case, has the potential to address a huge unmet need in patients suffering from Pseudomonas infections."

About Pieris Pharmaceuticals: Pieris is a clinical-stage biotechnology company advancing its proprietary Anticalin ® technology to create differentiated drugs that have the potential to be safer and more effective than conventional approaches. Anticalins show promise in addressing high-unmet medical needs and expanding the potential of targeted therapeutics. The company currently has a diverse proprietary pipeline and has ongoing R&D collaborations with Daiichi Sankyo, the Sanofi Group, Zydus Cadila, Stelis Biopharma and Allergan. Anticalin ® , Anticalins ® are registered trademarks of Pieris. For more information visit www.pieris.com .

About the Pieris-Sanofi infectious disease program: Under a collaboration and license agreement Pieris has used its proprietary Anticalin® technologies to identify drug candidates against certain targets, with further development and commercialization activities to be conducted by Sanofi. The partnered Pieris-Sanofi infectious disease program is a tetraspecific Anticalin-based protein that engages several bacterial siderophores from Pseudomonas aeruginosa as therapeutic targets. Bacterial infections depend on available iron levels, and bacteria such as Pseudomonas use siderophores for iron scavenging. The siderophores of Pseudomonas encompass three different classes of pyoverdins, each class comprising three different members, and pyochelin, altogether defining ten distinct targets. As the Anticalins in this program bind to these siderophores in an iron-bound and -- unbound state, the multispecific Anticalin protein effectively engages twenty targets. Pseudomonas is the most common pathogen isolated from patients who have been hospitalized longer than one week and is a frequent cause of nosocomial infections.

Forward-Looking Statements This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods; our business and product development plans; our liquidity and ability to fund our future operations; or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov , including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and the Company's Quarterly Reports on Form 10-Q.

Company Contact: Pieris Pharmaceuticals, Inc. Darlene Deptula-Hicks Sr. VP and Chief Financial Officer +1-603-553-5803 deptula@pieris.com Investor Relations Contact: The Trout Group Thomas Hoffmann +1-646-378-2931 thoffmann@troutgroup.com or Media Inquiries: Gretchen Schweitzer +49 172 861 8540 gschweitzer@macbiocom.com The Del Mar Consulting Group, Inc. Robert Prag President +1-858-794-5000 bprag@delmarconsulting.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 68

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Broadridge Brings Boyman In to Sharpen Its Market Story

Updated Category News Views 66

Financial plumbing rarely gets applause, which is precisely why Broadridge needs somebody who can explain its value without turning the pitch into alphabet soup. Lauren Boyman arrives as chief marketing and communications officer on November 23, taking charge of global marketing, corporate communications, product positioning, digital strategy, lead generation and thought...

Continue Reading
Frontline Claims Survey Tests AI's Real Desk Impact

Updated Category News Views 45

Claims software can look brilliant in a conference-room demo and still create a fresh pile of headaches for the person handling a real injured worker’s file. That is why the 2026 Workers’ Compensation Benchmarking Study opening its survey to frontline claims professionals matters more than the usual industry questionnaire. This is an operating-reality check, not just...

Continue Reading
1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 14

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
Trucking Hub Bets on Faster MVR Checks Nationwide Today

Updated Category News Views 38

Driver paperwork is where plenty of supposedly modern fleet systems still go to die. Trucking Hub’s Nov. 18 launch of GetMVR.com takes a clean swing at that mess: an online platform for ordering Motor Vehicle Records in all 50 states, with instant reports available in 48. It is not glamorous software, and frankly that is why it may matter. Fleets do not lose sleep over...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 180

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 167

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
Health In Tech Brings a Tech Veteran Onto Its Board

Updated Category News Views 31

Board appointments rarely make the cash register ring, but they can tell you where management thinks the next bruises are coming from. Health In Tech has added Tim Cortes as an independent director, put him in charge of the Compensation Committee, and placed him on both the Audit and Nominating and Corporate Governance Committees. For an AI-enabled insurance technology...

Continue Reading
De Beers Puts Namibia's 176-Carat Owishi on Display

Updated Category News Views 54

A 176-carat natural diamond can still make a room stop breathing, even in a trade battered by arguments over lab-grown supply, luxury spending, and what “rare” ought to mean anymore. De Beers Group, working with Grandview Klein Diamond, has unveiled Namibia’s Owishi natural diamond in Washington, DC. That is the hard fact on the table: a large Namibian stone, a U.S....

Continue Reading
Katahdin's Portland Branch Bet Moves Downtown in 2027

Updated Category News Views 0

Exchange Street is getting a real-world vote of confidence, and that is more interesting than another app update ever will be. Katahdin Trust intends to open a full-service branch at 120 Exchange Street in downtown Portland, with renovations slated to begin early in 2027 and an opening expected later that year. For a Maine community bank with nearly $1.2 billion in...

Continue Reading

Top 5 Most Recently Viewed Articles

Cohen & Steers to Release Q2 2026 Results Soon

Updated Category News Views 30

Mark Your Calendars: July 16 Q2 2026 Results There's a buzz in the air, folks. Cohen & Steers, Inc. (NYSE: CNS) is gearing up to release its second-quarter results for 2026 on July 16, right after the market bell tolls. Now, for those in the know, the earnings release is less about the numbers dropping and more about the story they tell. On the next day, July 17, their...

Continue Reading
Legal Notice for Skye Bioscience and Perrigo Investors Amid Lawsuits

Updated Category News Views 236

Overview of Ongoing Legal Matters for Investors Bragar Eagel & Squire, P.C., a prominent law firm specializing in investor rights, wishes to inform shareholders about class action lawsuits that have been initiated against Skye Bioscience, Inc. (NASDAQ: SKYE) and Perrigo Company plc (NYSE: PRGO). These lawsuits present a vital opportunity for investors to advocate for...

Continue Reading
JD.com Shares Insights on Upcoming Financial Releases

Updated Category News Views 136

JD.com Announces Upcoming Financial Report JD.com, Inc. (NASDAQ: JD) is gearing up to release its unaudited financial results for the fourth quarter and full year of 2024. This significant announcement is scheduled for March 6, 2025, and will provide investors with a detailed look into the company's performance. Conference Call Details As part of this release, JD.com's...

Continue Reading
Marketing Maven Public Relations Celebrated for Industry Disruption

Updated Category News Views 146

Marketing Maven Public Relations and Its Notable Recognition Marketing Maven Public Relations has truly made a mark in the public relations and marketing landscape, earning recognition as a nominee for the prestigious Disruptors Awards. This accolade celebrates organizations that pioneer innovative strategies, demonstrate strategic leadership, and make impactful changes...

Continue Reading
OneMedNet Unveils Groundbreaking Platform Advancements

Updated Category News Views 132

Introduction to OneMedNet's Innovative Platform OneMedNet Corporation, a notable player in the healthcare technology field, is gearing up to showcase a groundbreaking data exploration platform at RSNA 2025. This platform, which has received enthusiastic validation from clients and industry experts, marks a significant leap in how healthcare entities manage and analyze...

Continue Reading